J CLIN PSYCHOPHARM

Publications

  1. 2019
  2. Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013

    Langner, I., Haug, U., Scholle, O., Lindemann, C., Schröder, C. & Riedel, O., 2019, In: Journal of clinical psychopharmacology. 39, 1, p. 39-45 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  3. 2018
  4. Myocarditis During Treatment With Clozapine in 2 Adolescent Cases

    Mudra, S., Luedecke, D., Grafmann, M. & Schulte-Markwort, M., 10.2018, In: J CLIN PSYCHOPHARM. 38, 6, p. 639-640 2 p.

    Research output: SCORING: Contribution to journalOther (editorial matter etc.)Research

  5. 2015
  6. Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial

    Falcato, L., Beck, T., Reimer, J. & Verthein, U., 01.04.2015, In: J CLIN PSYCHOPHARM. 35, 2, p. 150-7 8 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  7. 2013
  8. No effects of antidepressants on negative symptoms in schizophrenia

    Hinkelmann, K., Yassouridis, A., Kellner, M., Jahn, H., Wiedemann, K. & Raedler, T. J., 01.10.2013, In: J CLIN PSYCHOPHARM. 33, 5, p. 686-90 5 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  9. 2011
  10. Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models.

    Lambert, M., Schimmelmann, B. G., Schacht, A., Suarez, D., Haro, J. M., Novick, D., Wagner, T., Wehmeier, P. M., Huber, C., Hundemer, H-P., Dittmann, R. W. & Naber, D., 2011, In: J CLIN PSYCHOPHARM. 31, 2, p. 226-230 2.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  11. 2010
  12. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.

    Schennach-Wolff, R., Obermeier, M., Seemüller, F., Jäger, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L. G., Gaebel, W., Klosterkötter, J., Heuser, I., Maier, W., Lemke, M. R., Rüther, E., Klingberg, S., Gastpar, M., Engel, R. R., Möller, H-J. & Riedel, M., 2010, In: J CLIN PSYCHOPHARM. 30, 6, p. 726-731 6.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  13. Low serotonergic function and its normalization by treatment with sertraline in obsessive-compulsive disorder--an auditory evoked potential study.

    Mavorgiorgou, P., Gohle, D., Winter, C., Rujescu, D., Pogarell, O., Mulert, C., Bär, K-J., Zaudig, M., Hegerl, U. & Juckel, G., 2010, In: J CLIN PSYCHOPHARM. 30, 3, p. 341-343 3.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  14. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.

    Hasan, A., Rothenberger, A., Münchau, A., Wobrock, T., Falkai, P. & Roessner, V., 2010, In: J CLIN PSYCHOPHARM. 30, 2, p. 190-192 2.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  15. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis.

    Lambert, M., Conus, P., Cotton, S., Robinson, J., McGorry, P. D. & Schimmelmann, B. G., 2010, In: J CLIN PSYCHOPHARM. 30, 5, p. 565-572 5.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  16. Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: lessons from a stopped trial?

    Kellner, M., Muhtz, C. & Wiedemann, K., 2010, In: J CLIN PSYCHOPHARM. 30, 4, p. 471-473 4.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  17. 2006
  18. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?

    Beasley, C. M., Sutton, V. K., Taylor, C. C., Sethuraman, G., Dossenbach, M. & Naber, D., 2006, In: J CLIN PSYCHOPHARM. 26, 1, p. 40-44 1.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  19. Remission and Relapse in the Outpatient Care of Schizophrenia: Three-year Results From the Schizophrenia Outpatient Health Outcome Study.

    Haro, J. M., Novick, D., Suarez, D., Alonso, J., Lepine, J. P., Ratcliffe, M., SOHO Study Group & Lambert, M., 2006, In: J CLIN PSYCHOPHARM. 26, p. 571-578

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  20. 2005
  21. The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study.

    Wolf, K., Mass, R., Kiefer, F., Eckert, K., Stritzky, A. V., Haasen, C., Wiedemann, K. & Naber, D., 2005, In: J CLIN PSYCHOPHARM. 25, 3, p. 278-281 3.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  22. 2004
  23. Risperidone in the treatment of acute schizophrenia.

    Raedler, T. J., Schreiner, A., Naber, D. & Wiedemann, K., 2004, In: J CLIN PSYCHOPHARM. 24, 3, p. 335-338 3.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  24. Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study.

    Otte, C., Wiedemann, K., Yassouridis, A. & Kellner, M., 2004, In: J CLIN PSYCHOPHARM. 24, 1, p. 106-108 1.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review